NRX Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
NRX Pharmaceuticals, Inc. (NRXP) reported Net Income (Loss) Available to Common Stockholders, Basic of -$25.13 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2025-03-14
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-12-31 was -$10.24M.
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$9.08M.
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$6.98M.
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$13.45M.
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$25.13M.
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$30.16M.
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$39.75M.
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$348.88M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$25.13M 10-K · filed 2025-03-14 | ||||||
| 2023-12-31 | -$30.16M 10-K · filed 2025-03-14 | ||||||
| 2022-12-31 | -$10.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$19.32M derived: sum of 2 quarters · filed 2023-03-31 | -$26.31M derived: sum of 3 quarters · filed 2023-03-31 | -$39.75M 10-K · filed 2023-03-31 | |||
| 2022-09-30 | -$9.08M 10-Q · filed 2022-11-14 | -$16.07M derived: sum of 2 quarters · filed 2022-11-14 | -$29.51M 10-Q · filed 2022-11-14 | -$59.92M derived: sum of 4 quarters · filed 2023-03-31 | |||
| 2022-06-30 | -$6.98M 10-Q · filed 2022-08-15 | -$20.43M 10-Q · filed 2022-08-15 | -$50.84M derived: sum of 3 quarters · filed 2023-03-31 | -$87.89M derived: sum of 4 quarters · filed 2023-03-31 | |||
| 2022-03-31 | -$13.45M derived: 10-K 12 month − 3 quarters · filed 2023-03-31 | -$43.85M derived: sum of 2 quarters · filed 2023-03-31 | -$80.90M derived: sum of 3 quarters · filed 2023-03-31 | -$336.84M derived: sum of 4 quarters · filed 2023-03-31 | |||
| 2021-12-31 | -$30.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$67.46M derived: sum of 2 quarters · filed 2023-03-31 | -$323.40M derived: sum of 3 quarters · filed 2023-03-31 | -$348.88M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$37.05M 10-Q · filed 2022-11-14 | -$20.77M 10-Q · filed 2021-11-15 | -$292.99M derived: sum of 2 quarters · filed 2022-11-14 | -$318.48M 10-Q · filed 2022-11-14 | -$318.09M 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | -$255.94M 10-Q · filed 2022-08-15 | -$271.83M 10-Q · filed 2021-08-16 | -$281.43M 10-Q · filed 2022-08-15 | -$297.32M 10-Q · filed 2021-08-16 | |||
| 2020-12-31 | -$45.13M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | -$50.29M derived: sum of 2 quarters · filed 2022-08-12 | -$50.19M derived: sum of 3 quarters · filed 2022-08-12 | -$51.78M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | -$5.16M 10-Q/A · filed 2022-08-12 | -$125.78K 10-Q · filed 2020-11-16 | -$5.06M derived: sum of 2 quarters · filed 2022-08-12 | -$6.65M 10-Q/A · filed 2022-08-12 | -$2.06K 10-Q · filed 2020-11-16 | -$4.85M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2020-06-30 | $102.29K 10-Q/A · filed 2022-08-12 | -$149.50K 10-Q · filed 2020-08-14 | -$1.49M 10-Q/A · filed 2022-08-12 | $123.72K 10-Q · filed 2020-08-14 | $315.86K derived: sum of 3 quarters · filed 2022-08-12 | $215.56K derived: sum of 4 quarters · filed 2022-08-12 | |
| 2020-03-31 | $273.22K 10-Q · filed 2020-05-15 | $213.57K derived: sum of 2 quarters · filed 2020-05-15 | $113.28K derived: sum of 3 quarters · filed 2020-11-16 | $29.57K derived: sum of 4 quarters · filed 2020-11-16 | |||
| 2019-12-31 | -$59.65K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$159.94K derived: sum of 2 quarters · filed 2020-11-16 | -$243.65K derived: sum of 3 quarters · filed 2020-11-16 | -$295.47K 10-K · filed 2020-03-30 | |||
| 2019-09-30 | -$100.29K 10-Q · filed 2020-11-16 | -$184.00K derived: sum of 2 quarters · filed 2020-11-16 | -$235.81K 10-Q · filed 2020-11-16 | -$511.52K derived: sum of 4 quarters · filed 2020-11-16 | |||
| 2019-06-30 | -$83.71K 10-Q · filed 2020-08-14 | -$154.94K 10-Q · filed 2020-08-14 | -$411.23K derived: sum of 3 quarters · filed 2020-08-14 | -$571.39K derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | -$84.42K 10-Q · filed 2020-05-15 | -$327.52K derived: sum of 2 quarters · filed 2020-05-15 | -$487.68K derived: sum of 3 quarters · filed 2020-05-15 | -$652.60K derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | -$243.10K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$403.26K derived: sum of 2 quarters · filed 2020-03-30 | -$568.18K derived: sum of 3 quarters · filed 2020-03-30 | -$748.86K 10-K · filed 2020-03-30 | |||
| 2018-09-30 | -$160.16K 10-Q · filed 2019-11-14 | -$325.08K derived: sum of 2 quarters · filed 2019-11-14 | -$505.76K 10-Q · filed 2019-11-14 | -$1.19K 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | -$164.92K 10-Q · filed 2019-08-14 | -$346.45K 10-Q · filed 2019-08-14 | -$445.38K derived: sum of 3 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | -$169.57K 10-Q · filed 2019-05-15 | -$280.45K derived: sum of 2 quarters · filed 2019-05-15 | |||||
| 2017-12-31 | -$110.88K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |